Adamas Pharmaceuticals, Inc.
(NASDAQ : ADMS)

( )
ADMS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-1.83%19.292.0%$636.97m
SHPGShire PLC Sponsored ADR
1.03%172.170.4%$144.47m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.06%143.236.8%$139.89m
PRGOPerrigo Co. Plc
2.42%71.866.8%$99.72m
JAZZJazz Pharmaceuticals Plc
-2.24%155.272.2%$67.34m
ENDPEndo International Plc
-0.17%17.488.9%$62.01m
MNKMallinckrodt Plc
0.07%27.1821.1%$60.38m
ICPTIntercept Pharmaceuticals, Inc.
-2.12%101.5318.7%$49.22m
SAGESAGE Therapeutics, Inc.
-3.66%120.259.6%$48.34m
UTHRUnited Therapeutics Corporation
0.25%123.4214.4%$36.83m
CTLTCatalent Inc
0.22%41.562.4%$33.68m
ICLRICON Plc
-0.52%144.164.1%$32.82m
AERIAerie Pharmaceuticals, Inc.
1.57%56.246.9%$27.13m
PCRXPacira Pharmaceuticals, Inc.
2.67%45.3210.6%$26.60m
PTLAPortola Pharmaceuticals, Inc.
-2.83%23.377.7%$26.18m

Company Profile

Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease. The ADS-401 treats partial onset seizures in patients with epilepsy. The Namenda XR is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.